Prof. Paul Jules Declerck

received all his scientific degrees with Great Distinctions at the Catholic University in Leuven - the degree of Pharmacist in 1980, the Teaching diploma in Pharmaceutical Sciences for Higher Secondary &Technical Schools in 1983, and the Ph. D. in Pharmaceutical Sciences in 1984. He did his postdoctoral fellowship in The Rockefeller University, NY (1985-1986). In 1994-1996 he was employed as a Professor at the Faculty of Pharmaceutical Sciences in Catholic University of Leuven and since 1997 he is a Full Professor in the same Faculty. In 1998-2001 he was elected to be the Vice-Dean, and in 2001 the Dean of the Faculty of Pharmaceutical Sciences in Catholic University of Leuven. Professor Paul Declerck was invited to give Lectures at a number of international meetings and received several prestigious international Awards and Prizes. He published over 125 scientific papers in international peer-reviewed journals on different structural, functional and clinical aspects of plasminogen activator inhibitor type 1 (PAI-1).

 

The following are some of the most representative papers published by his laboratory during the last three years:

Isogai C, Laug WE, Shimada H, Declerck PJ, Stins MF, Erdreich-Epstein A, DeClerck YA. Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration towards fibronectin. Cancer Res 61, 5587-5594, 2001.

Ngo TH, Hoylaerts MF, Knockaert I, Brouwers E, Declerck PJ. Identification of a target-site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitory properties concomitant with an allosteric upregulation of its anti-adhesive properties. J Biol Chem 276, 26243-26248, 2001.

Bijnens AP, Gils A, Stassen JM, Komissarov AA, Knockaert I, Brouwers E, Shore JD, Declerck PJ. The distal hinge of the reactive site loop and its proximity: a target to modulate plasminogen activator inhibitor-1. J Biol Chem 276, 44912-44918, 2001.

Eren M, Painter CA, Atkinson JB, Declerck PJ, Vaughan DE. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation 106, 491-496, 2002.

Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noël A, Foidart JM. The pro-or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 16, 147-154, 2002.

Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activatior inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 277, 43858-43865, 2002.

De Taeye B, Compernolle G, Dewilde M, Biesemans W, Declerck PJ. Immobilization of the distal hinge in the labile serpin PAI-1: Identification of a transition state with distinct conformational and functional properties. J Biol Chem 26, 23899-23905, 2003.

Roca C, Primo L, Valdembri D, Cividalli A, Declerck P, Carmeliet P, Gabriele P, Bussolino F. Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor-1 dependent mechanism. Cancer Research 63, 1500-1507, 2003.
Verheyden S, Gils A, Sillen A, Declerck PJ, Engelborghs Y. Tryptophan properties in fluorescence and functional stability of plasminogen activator inhibitor 1. Biophysical Journal 85, 501-510, 2003.